[{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Millicent Pharma Limited","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Divestment","leadProduct":"Prasterone","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"AMAG Pharmaceuticals","amount2":0.13,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.13,"dosageForm":"Intravaginal","sponsorNew":"AMAG Pharmaceuticals \/ Millicent Pharma Limited","highestDevelopmentStatusID":"12","companyTruncated":"AMAG Pharmaceuticals \/ Millicent Pharma Limited"},{"orgOrder":0,"company":"Theramex","sponsor":"Endoceutics","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Prasterone","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Theramex","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Pessary","sponsorNew":"Theramex \/ Endoceutics","highestDevelopmentStatusID":"12","companyTruncated":"Theramex \/ Endoceutics"},{"orgOrder":0,"company":"Endoceutics","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Prasterone","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Endoceutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Insert","sponsorNew":"Endoceutics \/ Cosette Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Endoceutics \/ Cosette Pharma"}]

Find Clinical Drug Pipeline Developments & Deals for Prasterone

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : The acquisition accelerates Cosette’s women’s health portfolio, with a differentiated, commercial stage, patent protected product, Intrarosa (prasterone), the only prescription drug providing both estrogen and androgen for the treatment of moderate-t...

                          Brand Name : Intrarosa

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 08, 2023

                          Lead Product(s) : Prasterone

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved

                          Sponsor : Cosette Pharma

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          02

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Intrarosa is now available in this market as the first and only locally acting DHEA (dehydroepiandrosterone) treatment indicated for postmenopausal women experiencing moderate to severe symptoms associated with vulvovaginal atrophy (VVA).

                          Brand Name : Intrarosa

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          February 14, 2022

                          Lead Product(s) : Prasterone

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved

                          Sponsor : Endoceutics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Transaction allows AMAG to advance its strategic focus on Feraheme, Makena and its pipeline, consistent with previously announced plans.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : $20.0 million

                          May 21, 2020

                          Lead Product(s) : Prasterone

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Millicent Pharma Limited

                          Deal Size : $125.0 million

                          Deal Type : Divestment

                          blank